IP Verse

Subcutaneous Formulations Of Anti-Cd38 Antibodies And Their Uses

Patent No. EP3370770 (titled "Subcutaneous Formulations Of Anti-Cd38 Antibodies And Their Uses") was filed by Janssen Biotech on Nov 1, 2016. The application was issued on Jan 20, 2021.

Patent Summary

Subcutaneous injection of anti-CD38 antibodies for treating cancers like multiple myeloma, using a hyaluronidase enzyme to reduce viscosity and improve tissue penetration. The composition contains an anti-CD38 antibody at 20 mg/mL concentration and a hyaluronidase like rHuPH20 at 500 U/mL. The hyaluronidase helps the subcutaneous injection reach deeper tissues by breaking down hyaluronic acid in the extracellular matrix.

Patent Family

Patent Family

Patent Oppositions (5)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
BREUEROct 20, 2021DORRIES
BREUEROct 20, 2021DORRIES, HANS ULRICH , DF-MP DORRIES FRANK-MOLNIA & POHLMAN
PATENT BOUTIQUEOct 19, 2021PATENT BOUTIQUE
KONIG SZYNKA TILMANN VON RENESSEOct 6, 2021KONIG SZYNKA TILMANN VON RENESSE DUSSELDORF
KONIG SZYNKA TILMANN VON RENESSEOct 6, 2021KONIG SZYNKA TILMANN VON RENESSE PATENTANWALTE PARTNERSCHAFT MBB DUSSELDORF

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3370770

JANSSEN BIOTECH
Application Number
EP16862791A
Filing Date
Nov 1, 2016
Status
Revoked
Jan 22, 2025
Publication Date
Jan 20, 2021
External Links
Slate, Register , Google Patents